Ipca Laboratories' FY25 Profit Up by 35%
By Ankur Chandra | Updated at: May 31, 2025 10:45 PM IST
Ipca Laboratories Ltd reported a consolidated net profit of ₹737.68 crore for the financial year ended March 31, 2025, marking a 35% YoY growth over ₹547.35 crore in FY24. The pharmaceutical major also posted a 16% jump in annual revenue to ₹8,939.59 crore, driven by robust domestic formulations and steady export contributions.
Consolidated Financial Highlights (FY25 vs FY24)
| Particulars | FY25 (₹ Cr) | FY24 (₹ Cr) | YoY Change |
|---|---|---|---|
| Revenue from Operations | 8,939.59 | 7,705.04 | +16% |
| Total Income | 9,032.39 | 7,829.81 | +15% |
| EBITDA (before exceptional items) | 1,693.13 | 1,288.21 | +31% |
| Net Profit (before exceptional items) | 992.58 | 636.96 | +56% |
| Net Profit (after exceptional items) | 737.68 | 547.35 | +35% |
| EPS (Basic, after exceptional items) | ₹29.08 | ₹21.57 | +35% |
| Total Comprehensive Income | 760.69 | 513.47 | +48% |
Q4 FY25 Results Snapshot
| Particulars | Q4 FY25 (₹ Cr) | Q4 FY24 (₹ Cr) | YoY Change |
|---|---|---|---|
| Revenue from Operations | 2,246.69 | 2,033.03 | +11% |
| Total Income | 2,272.51 | 2,051.95 | +11% |
| EBITDA (before exceptional items) | 409.74 | 304.59 | +35% |
| Net Profit (before exceptional items) | 270.83 | 139.63 | +94% |
| Net Profit (after exceptional items) | 67.82 | 59.59 | +14% |
| EPS (Basic, after exceptional items) | ₹2.67 | ₹2.35 | +14% |
Segment-Wise Revenue (FY25)
| Segment | FY25 (₹ Cr) | FY24 (₹ Cr) | Growth |
|---|---|---|---|
| Domestic Formulations | 3,455.10 | 3,097.16 | +12% |
| Exports | 2,808.96 | 2,707.70 | +4% |
| – Branded | 1,513.33 | 1,189.54 | +27% |
| – Institutional | 266.99 | 355.15 | -25% |
| – Generics | 1,028.64 | 1,163.01 | -12% |
| APIs – Domestic | 375.46 | 316.92 | +18% |
| APIs – Exports | 890.38 | 932.38 | -5% |
Key Financial Metrics
- EBITDA Margin: 18.94% in FY25 vs 16.72% in FY24
- PAT Margin (before exceptional): 11.1% in FY25 vs 8.3% in FY24
- Total Assets: ₹11,760.55 crore (↑6% YoY)
- Net Worth: ₹6,948.45 crore (↑10% YoY)
Exceptional Items (FY25 Total: ₹205.05 Cr)
| Particulars | Amount (₹ Cr) |
|---|---|
| Impairment of exposure in Associate (Krebs) | 118.90 |
| Impairment of Freehold Land (Niche Generics) | 86.15 |
Cash Flow Highlights (FY25)
- Net Cash from Operating Activities: ₹1,321.32 crore (↑40% YoY)
- Net Cash used in Investing Activities: ₹869.50 crore
- Capex (incl. CWIP and intangibles): ₹775.52 crore
- Closing Cash & Equivalents: ₹924.63 crore
Corporate Announcements
- The company has proposed a final dividend of ₹2 per share (200%) for FY25.
- 100% acquisition of Unichem Laboratories Ltd. (Ireland) completed post year-end.
- Closure of Niche Generics Ltd. UK plant, with shift of production to India for operational efficiency.
- Segment revenue from outside India stood at ₹4,897.57 crore, accounting for 55% of total operations.
Management Commentary
Executive Chairman Premchand Godha said: “FY25 has been a pivotal year in Ipca’s growth journey with improved profitability, margin expansion, and portfolio optimization. We continue to focus on sustainable growth through domestic leadership and global integration.”
Outlook
Ipca Laboratories remains focused on expanding branded exports, consolidating efficiencies post-Unichem integration, and tapping newer global markets, while investing in capacity and R&D for long-term growth.
Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. Please read the offer documents carefully before investing. Investments are subject to market risks and other risks. There is no guarantee of the actual returns that will be given.
REF: https://nsearchives.nseindia.com/corporate/IPCALAB_29052025135520_IpcaQ4FY25Results.pdf
